Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisisCAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle cell disease and their caregivers, and Fulcrum Therapeutics Inc. (Fulcrum) (Nasdaq: FULC), a leader in advancing ther ...

Fulcrum Therapeutics Conference Call Summary Company Overview - **Company**: Fulcrum Therapeutics (NasdaqGM: FULC) - **Focus**: Development of treatments for sickle cell disease, specifically the drug pociredir Key Industry Insights - **PIONEER Study Results**: The full data from the PIONEER study was recently announced, showing promising results in increasing fetal hemoglobin (HbF) levels in patients with sickle cell disease. The average HbF increased from 7.1% to 19.3%, a delta of 12.2% [3][4] - **Physician Feedback**: The physician community has responded positively to the data, particularly regarding the rapid induction of HbF and the reduction in hemolysis markers [3][4] - **Vaso-Occlusive Crises (VOCs)**: The study observed only 6 VOCs compared to the expected 16 over 12 weeks, with 7 out of 12 patients experiencing no VOCs during treatment [6][10] Clinical Data Highlights - **HbF Levels**: Almost 60% of patients achieved HbF levels of at least 20%, while all patients saw an increase of at least 6.5% [10][11] - **Patient Variability**: Some patients did not reach the 20% HbF mark, but even smaller increases were deemed clinically meaningful, potentially reducing hospital admissions [11] - **Geographic Factors**: Variability in patient responses may be influenced by geographic factors, particularly in patients from the Democratic Republic of Congo, who may have a specific haplotype associated with lower HbF levels [13][15] Regulatory and Development Plans - **FDA Engagement**: The company plans to propose a registrational study to the FDA, potentially using HbF as a surrogate endpoint for accelerated approval, with a focus on a severe patient population [21][23] - **Study Design**: The registrational study is expected to involve 200-300 patients, with an interim look at HbF levels at the six-month mark [23][24] - **EMA Engagement**: The company will engage with the European Medicines Agency (EMA) mid-year, aiming for harmonization in clinical development programs [29][30] Financial and Strategic Outlook - **Cash Runway**: Fulcrum Therapeutics has sufficient cash reserves to fund operations through 2029, focusing primarily on the sickle cell program [42] - **Future Aspirations**: The company aims to become a leading benign hematology company, exploring both internal discovery and potential in-licensing opportunities [43][44] - **DBA Program Discontinuation**: The company has decided to discontinue its DBA program to concentrate resources on the sickle cell initiative [47][48] Market Considerations - **Impact of Competitors**: The recent withdrawal of Ipsen's Tazverik has raised questions about the implications for pociredir, although the two drugs target different mechanisms [36][38][39] - **Partnership Potential**: While the company aims to commercialize pociredir in the U.S. independently, it may consider partnerships for international markets [40][41] Conclusion Fulcrum Therapeutics is positioned to advance its sickle cell treatment program with promising clinical data and a clear regulatory strategy, while also maintaining a focus on financial sustainability and future growth in benign hematology.

Company Overview - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases [3] - The company's lead clinical program is pociredir, a small molecule designed to increase the expression of HbF for the treatment of sickle cell disease (SCD) [3] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root cause of gene mis-expression [3] Upcoming Events - Company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on March 10, 2025, at 1:00 p.m. ET [1] - The presentation will be accessible via a webcast, which will also be available for replay on the company's website for at least 30 days following the event [2]

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent risks and volatility associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the predictions and opinions presented are based on a probabilistic approach rather than absolute certainty [2]. - The author has no financial interest in the companies mentioned, ensuring an unbiased perspective [1]. Group 2 - The article stresses that past performance is not indicative of future results, cautioning readers against relying solely on historical data [3]. - It notes that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article highlights that the analysts may not be licensed or certified, which could affect the reliability of the information provided [3].

Core Viewpoint - The recent decline in Fulcrum Therapeutics (FULC) shares is considered excessive by Stifel analyst James Condulis, who believes the market is overlooking the broader implications of the company's data [1]. Group 1: Analyst Insights - Stifel's analysis suggests that the total mean HbF levels may exceed 20%, indicating strong initial results from the ASH conference [1]. - The firm argues that focusing on a specific figure of 19.3% is overly critical and misses the overall positive data that surpasses physician expectations [1]. - The analyst maintains a Buy rating on Fulcrum shares with a price target of $25, highlighting the potential of a late-stage asset in the sickle cell disease market [1]. Group 2: Market Context - The shares of Fulcrum Therapeutics are currently undervalued, reflecting a significant discount despite the promising data and validated mechanism of action [1]. - The company's pociredir is achieving HbF levels that are expected to provide substantial protection against the disease, reinforcing its market potential [1].

Financial Data and Key Metrics Changes - The 20 mg cohort of pociredir showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [9][15] - Total hemoglobin increased by more than 1 g/dL after 12 weeks of treatment [9][20] - The safety profile of pociredir at the 20 mg dose remains generally well-tolerated, with no treatment-related serious adverse events reported [21][80] Business Line Data and Key Metrics Changes - In the 20 mg cohort, 58% of patients achieved HbF levels at or above 20%, which is associated with clinically meaningful protection [9][15] - The cohort demonstrated a 34% reduction in lactate dehydrogenase (LDH) and a 40% reduction in indirect bilirubin, indicating reduced hemolysis [18] - A 42% drop in reticulocytes was observed, reflecting decreased bone marrow stress due to reduced hemolysis [19] Market Data and Key Metrics Changes - The unmet medical need for sickle cell disease treatments remains significant, with current options limited primarily to hydroxyurea [25][86] - The global sickle cell disease population is estimated at 7.7 million, with a substantial number in Sub-Saharan Africa [90] Company Strategy and Development Direction - The company plans to initiate a potential registration-enabling trial in the second half of 2026, pending feedback from the FDA [31] - Engagement with the European Medicines Agency is planned for mid-2026 to obtain protocol assistance [31] - The company aims to maintain a competitive edge in the market, believing it has a two-year head start over competitors [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly reduce vaso-occlusive crises and hemolytic anemia in sickle cell disease patients [25][26] - The management highlighted the importance of advancing into a registration-enabling study due to the robust data generated [51][82] - There is a strong belief that if results are replicated in late-phase clinical trials, pociredir could serve as a first-line therapy for sickle cell disease [29] Other Important Information - The 20 mg cohort had no transfusions during the treatment period, contrasting with the 12 mg cohort [20] - The study design included a high degree of disease severity among participants, which is critical for understanding treatment efficacy [12] Q&A Session Summary Question: Can you provide insight into the VOC data and when they occurred? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [35] Question: How well does the 20 mg cohort represent the broader sickle cell patient population? - The 20 mg cohort is believed to represent a middle slice of the global population, with more heterogeneity observed in patients from Nigeria compared to South Africa [36][38] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, are expected to show changes over time as HbF levels increase [41][43] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data and the biological relationship between HbF levels and clinical outcomes with the FDA [51][52] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established treatment showing sustained effects, and many patients still experiencing severe events [86]

Financial Data and Key Metrics Changes - The 20-milligram cohort of the phase 1b PIONEER trial showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [6][13] - Total hemoglobin increased by more than 1 gram per deciliter after 12 weeks of treatment [7][18] - A reduction of 34% in lactate dehydrogenase (LDH) and 40% in indirect bilirubin was observed, indicating decreased hemolysis [16] Business Line Data and Key Metrics Changes - The 20-milligram cohort demonstrated that over half of the patients achieved HbF levels at or above 20%, which is historically associated with clinically meaningful protection [6][8] - The cohort consisted of 12 evaluable patients, with 7 reporting no vaso-occlusive crises (VOCs) during the treatment period [7][19] Market Data and Key Metrics Changes - The unmet medical need for sickle cell disease treatments remains significant, with mortality rates elevated and life expectancy reduced despite advances in clinical care [9] - The 20-milligram cohort included patients from Nigeria, reflecting a more heterogeneous population compared to previous cohorts [37] Company Strategy and Development Direction - The company plans to provide an update on the next trial design in Q2 2026 and aims to initiate a potential registration-enabling trial in the second half of 2026 [30] - The strategy includes engaging with the European Medicines Agency for protocol assistance and feedback on the next trial [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly reduce acute vaso-occlusive events and hemolytic anemia in sickle cell disease patients [24][29] - The company believes it has a two-year head start over competitors in the market for fetal hemoglobin-inducing agents [76] Other Important Information - Pociredir continues to be generally well-tolerated at the 20-milligram dose, with no treatment-related serious adverse events reported [19][20] - The company has dosed almost 150 adults to date, with no dose-limiting toxicities observed [20] Q&A Session Summary Question: Can you provide additional insight into the VOCs and when they occurred during the study? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [34] Question: How well does the 20-milligram cohort represent the population of sickle cell patients? - The cohort is likely more representative of the global population, with a more heterogeneous haplotype distribution [37] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, may take longer to reflect the full effects of HbF induction [41][44] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data supporting HbF induction and its association with improved clinical outcomes [50] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established treatment, and many patients continue to experience severe events despite treatment [85]

Financial Data and Key Metrics Changes - The 20-milligram cohort of the PIONEER trial showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [5][12] - Total hemoglobin increased by more than 1 gram per deciliter after 12 weeks of treatment [5][21] - The safety profile of pociredir at the 20-milligram dose remains generally well-tolerated, with no treatment-related serious adverse events reported [18][81] Business Line Data and Key Metrics Changes - In the 20-milligram cohort, 58% of patients achieved HbF levels at or above 20%, which is historically associated with clinically meaningful protection [5][12] - There was a 34% reduction in lactate dehydrogenase (LDH) and a 40% reduction in indirect bilirubin at week 12, indicating reduced hemolysis [15] - The cohort experienced a 42% drop in reticulocytes, reflecting decreased bone marrow stress due to reduced hemolysis [16] Market Data and Key Metrics Changes - Sickle cell disease remains a debilitating condition affecting millions globally, with significant unmet medical needs despite advances in clinical care [7] - The expected vaso-occlusive crises (VOCs) based on baseline data was 16 events over 12 weeks, but only 6 events were observed in 5 patients during the treatment period [17] Company Strategy and Development Direction - The company plans to provide an update on the next trial design in Q2 2026 and aims to initiate a potential registration-enabling trial in the second half of 2026 [29] - Engagement with the European Medicines Agency is planned for mid-2026 to obtain protocol assistance and feedback on the next trial design [29] - The company is activating sites for an open-label extension study for PIONEER patients to evaluate the longer-term safety and durability of response of pociredir [29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly impact the treatment of sickle cell disease, especially given the limitations of current therapies like hydroxyurea [22][86] - The unmet need for effective treatments in sickle cell disease is highlighted, especially following the withdrawal of certain therapies and the limited uptake of others [86] - The company believes it has a two-year head start over competitors in the market for fetal hemoglobin-inducing agents [78] Other Important Information - The 20-milligram cohort data reinforces the belief that pociredir is demonstrating a biological profile expected from a best-in-class oral HbF inducer for sickle cell disease [6] - The trial design included a high degree of disease severity among participants, with a focus on patients with significant baseline VOCs [9] Q&A Session Summary Question: Can you provide additional insight into when VOCs occurred during the study? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [32][34] Question: How well does the 20-milligram cohort represent the population of sickle cell patients? - The 20-milligram cohort is believed to represent a middle slice of the global population, with more heterogeneity in haplotypes compared to previous cohorts [35][37] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, are expected to show more immediate effects, while total hemoglobin may take longer to reflect the full impact of HbF induction [40][44] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data supporting HbF induction and its association with improved clinical outcomes in sickle cell disease [49][50] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established therapy showing sustained disease-modifying effects, and many patients still experiencing severe events [86]

Clinical Results - The mean absolute HbF increased by 12.2% at 12 weeks of treatment with pociredir, rising from a baseline of 7.1% to 19.3%[443] - Seven of 12 patients (58%) achieved absolute HbF levels ≥20% at Week 12, which is associated with ~90% of patients experiencing zero VOCs per year[443] - Mean hemoglobin increased by 1.1 g/dL at Week 12, from a baseline of 7.3 g/dL to 8.4 g/dL[443] Financial Performance - The company incurred net losses of $74.9 million and $9.7 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $594.3 million as of December 31, 2025[446] - Net loss increased by $65.2 million from $9.7 million in 2024 to $74.9 million in 2025, reflecting higher operating losses[466] - Cash, cash equivalents, and marketable securities totaled $352.3 million as of December 31, 2025, providing liquidity for ongoing operations[473] - Net cash used in operating activities was $60.1 million in 2025, a significant increase from $2.2 million in 2024, primarily due to higher net losses[477] - Net cash provided by financing activities was $168.7 million in 2025, significantly up from $2.7 million in 2024, mainly from a public offering[479] - The company expects to incur substantial operating losses and negative cash flows for the foreseeable future as it continues its research and development activities[480] - The company has not yet commercialized any product candidates and does not expect to generate revenue from product sales for several years[473] Research and Development - Research and development expenses totaled $56.1 million for the year ended December 31, 2025, a decrease from $63.4 million in 2024[459] - Pociredir external expenses increased to $19.99 million in 2025 from $8.58 million in 2024[459] - Research and development expenses decreased by $7.3 million from $63.4 million in 2024 to $56.1 million in 2025, mainly due to reduced external research costs and employee compensation[468] - The company plans to initiate a potential registration-enabling trial for pociredir in the second half of 2026, pending FDA feedback[442] - The company will focus resources on advancing pociredir and core benign hematology programs, discontinuing the program for bone marrow failure syndromes[445] Operating Expenses - Total operating expenses decreased by $17.1 million from $101.9 million in 2024 to $84.8 million in 2025, primarily driven by reductions in research and development and general administrative expenses[466] - General and administrative expenses decreased by $7.8 million from $36.4 million in 2024 to $28.7 million in 2025, attributed to lower employee compensation and professional services costs[469] Revenue and Funding - Collaboration revenue decreased by $80.0 million from $80.0 million in 2024 to $0 in 2025 due to the termination of the Sanofi collaboration agreement[467] - The company expects to finance operations through equity offerings, debt financings, and collaborations, indicating a need for substantial additional funding[447] Accounting and Financial Policies - The company recognizes revenue under ASC 606 when control of promised goods or services is obtained by the customer[490] - The company evaluates accrued research and development expenses based on estimates of services received and efforts expended, with adjustments made as necessary[495] - Stock-based compensation expense is expected to increase in future periods due to unrecognized stock-based compensation and additional awards granted[501] - The company does not currently hedge its foreign currency exchange rate risk, with minimal or no liabilities denominated in foreign currencies as of December 31, 2025[506] - Interest income is sensitive to changes in interest rates, but a 10% change would not materially affect the fair market value of the investment portfolio[505] - The company accounts for uncertain tax positions using a more-likely-than-not threshold, with no uncertain tax positions reported as of each balance sheet date[503] - The company has made an accounting policy election to account for research and development reimbursements as a reduction of expenses[488] - Inflation has not had a material effect on the company's business or financial condition during the years ended December 31, 2025 and 2024[507] - The company uses significant judgment to determine the transaction price and performance obligations in contracts under ASC 606[491]

Core Insights - Fulcrum Therapeutics announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD), showing a mean absolute HbF increase of 12.2% from a baseline of 7.1% to 19.3% at Week 12, along with improvements in hemolysis and anemia markers, and trends in vaso-occlusive crisis reduction [1][5][10] - The company plans to initiate a potential registration-enabling trial in the second half of 2026, following discussions with the FDA regarding the next study design [1][2][5] - As of December 31, 2025, Fulcrum had $352.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029 [1][8][15] Recent Business Highlights - The 20 mg cohort of the PIONEER trial included 12 participants and demonstrated significant HbF induction and safety, with no treatment-related serious adverse events reported [5][10] - Fulcrum completed a public offering in December 2025, raising $164.2 million in net proceeds, which bolstered its financial position for advancing pociredir and other corporate purposes [5][7] - The company has decided not to advance its program for bone marrow failure syndromes into clinical development, focusing resources on pociredir and its benign hematology pipeline [5][10] Financial Results - Research and development expenses for Q4 2025 were $15.4 million, up from $11.7 million in Q4 2024, primarily due to costs associated with the PIONEER trial [6][7] - General and administrative expenses for Q4 2025 were $7.3 million, a slight decrease from $7.7 million in Q4 2024, attributed to lower professional services costs [7] - The net loss for Q4 2025 was $20.3 million, compared to a net loss of $16.6 million in Q4 2024, while the annual net loss for 2025 was $74.9 million, significantly higher than the $9.7 million loss in 2024 [7][16]